Clinical Trial Update: Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial assessing a vaccine against essential hypertension has completed, with results evaluating safety, tolerability, and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Vaccine Against Essential Hypertension

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Mild Essential Hypertension, Moderate Essential Hypertension | Phase 2 | Status: COMPLETED